-
Measuring Quality of Life in Huntington’s Disease Using a Proxy Approach: Validation of the HD-mQoL-prx Measure
Sep 9, 2025, 16:22 PM -
Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review
Sep 9, 2025, 16:22 PM -
Is Lecanemab Worth the Wait? Real Option Value and the Cost of Future Innovation in Alzheimer's Disease
Sep 9, 2025, 16:22 PM -
Mapping the Landscape of Digital Healthcare Services Delivered by Specialized Oncology Hospitals in China: Qualitative Analytical Study
Sep 9, 2025, 16:22 PM -
Comparative Effectiveness of Alectinib vs. Crizotinib as First-Line Therapy in ALK-Positive Non-Small Cell Lung Cancer: A Real-World Quasi-Experimental Study
Sep 9, 2025, 16:22 PM -
Applicability of the STEDI Value Framework to Vaccines in Health Technology Assessment: Opportunities and Considerations
Sep 9, 2025, 16:22 PM -
Ensuring Greater Acceptance of Minimal Residual Disease Negativity in Health Technology Assessments in Multiple Myeloma: Key Barriers and Opportunities
Sep 9, 2025, 16:22 PM -
The AI-in-RWE Transparency (AIRT) Checklist: Essential and Desirable Standards for AI-Enhanced Real-World Evidence
Sep 9, 2025, 16:22 PM -
Exploring Nonproportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology
Sep 9, 2025, 16:22 PM -
Gender Inequalities in Aortic and Mitral Valve Replacement and Repair Procedures in Germany
Sep 9, 2025, 16:22 PM -
Modeling the Anticipated Organizational Impact on Health Service Provision of the Introduction of Tirbanibulin for the Topical Treatment of Actinic Keratosis in France: EPIKA Study
Sep 9, 2025, 16:22 PM -
Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada
Sep 9, 2025, 16:22 PM -
Patterns Of Adoption And Diffusion Of Biological Therapies In Inflammatory Bowel Disease: Patient-Centric Insights From Israel
Sep 9, 2025, 16:22 PM -
An Interactive Tool to Select Indirect Treatment Comparison Methods for Rapid Feasibility Assessment
Sep 9, 2025, 16:22 PM -
Differences in the Reimbursement Pathway for Ultraorphan Therapies in England and Ireland
Sep 9, 2025, 16:22 PM -
Budgetary Impact of Ultra-Rare Diseases in Brazil: A Review of Decisions From the Past Five Years
Sep 9, 2025, 16:22 PM -
Real-World Cost of Automated Red Blood Cell Exchange for Sickle Cell Disease in Kenya: A Cost-Reimbursement Gap Analysis From a Public Sector Perspective
Sep 9, 2025, 16:22 PM -
Enhancing Healthcare Cost Communication Through Visualization: A Decision Tree Framework
Sep 9, 2025, 16:22 PM -
Beyond the Conversation: A Narrative Review of Cost-Informed Shared Decision Making and Its Impact on Medication Adherence in Chronic Conditions
Sep 9, 2025, 16:22 PM -
Economic Evaluation of I-Medicine: An AI-Driven E-Medicine Platform for Reducing Adverse Drug Reactions and Healthcare Expenditures
Sep 9, 2025, 16:22 PM
